Pfizer's $25 support holds strong, with institutional buying signals and growth potential in oncology. Click here to read an ...

Haleon was formed in 2019 by the merger of the consumer healthcare businesses of British pharmaceutical group GSK and US ...

Haleon launched a share buyback programme of up to £330m on Friday, representing the remaining portion of the £500m allocated ...

Haleon offers plenty of stability amidst the current market volatility, with its Power Brands driving strong organic growth.

Cocoa extract supplementation among older adults had no effect overall on the occurrence of age-related macular degeneration ...

Global IPO markets made steady gains in 2024, with IPO proceeds increasing compared to the previous year as the high interest ...

Haleon shares were broadly unchanged at 390.4p after Pfizer offloaded its remaining 7.3% stake for £2.5 billion at a price of 385p. The shares were 330p when Pfizer spun off its original 32% ...

Kotak Alternate Asset Managers have announced an investment of ₹1,050 crore in Tirupati Medicare Ltd, a contract development ...

This year’s unexpected demand for European stocks is helping to drive the region’s largest wave of block sales this century, ...

Pfizer sells entire Haleon stake for $3.24 billion Drugmaker Pfizer has sold its entire stake in Haleon for about 2.5 billion pounds ($3.24 billion) to institutional investors and the consumer ...

AstraZeneca signed a deal with Alteogen worth up to $1.35 billion for subcutaneous cancer drugs. Taiho Pharmacetical bought ...